Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients

Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ni, Yanhong [verfasserIn] Wu, Wenhui [verfasserIn] Zhou, Hua [verfasserIn] Li, Min [verfasserIn] Zhu, Xiying [verfasserIn] Niu, Hongyan [verfasserIn] Liu, Jinfeng [verfasserIn] Xue, Lina [verfasserIn] Liu, Yeqian [verfasserIn] Yang, Min [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	Maintenance hemodialysis Ultrapure dialysate Central Dialysate Delivery system CDDS Inflammation

Anmerkung:	© The Author(s) 2024

Übergeordnetes Werk:	Enthalten in: BMC nephrology - BioMed Central, 2000, 25(2024), 1 vom: 19. Sept.
Übergeordnetes Werk:	volume:25 ; year:2024 ; number:1 ; day:19 ; month:09

Links:	Volltext

DOI / URN:	10.1186/s12882-024-03751-3

Katalog-ID:	SPR057390053

Internformat


LEADER	01000naa a22002652 4500
001	SPR057390053
003	DE-627
005	20240920064740.0
007	cr uuu---uuuuu
008	240920s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s12882-024-03751-3 \|2 doi
035			\|a (DE-627)SPR057390053
035			\|a (SPR)s12882-024-03751-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a 44.00 \|2 bkl
100	1		\|a Ni, Yanhong \|e verfasserin \|4 aut
245	1	0	\|a Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2024
520			\|a Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.
650		4	\|a Maintenance hemodialysis \|7 (dpeaa)DE-He213
650		4	\|a Ultrapure dialysate \|7 (dpeaa)DE-He213
650		4	\|a Central Dialysate Delivery system \|7 (dpeaa)DE-He213
650		4	\|a CDDS \|7 (dpeaa)DE-He213
650		4	\|a Inflammation \|7 (dpeaa)DE-He213
700	1		\|a Wu, Wenhui \|e verfasserin \|4 aut
700	1		\|a Zhou, Hua \|e verfasserin \|4 aut
700	1		\|a Li, Min \|e verfasserin \|4 aut
700	1		\|a Zhu, Xiying \|e verfasserin \|4 aut
700	1		\|a Niu, Hongyan \|e verfasserin \|4 aut
700	1		\|a Liu, Jinfeng \|e verfasserin \|4 aut
700	1		\|a Xue, Lina \|e verfasserin \|4 aut
700	1		\|a Liu, Yeqian \|e verfasserin \|4 aut
700	1		\|a Yang, Min \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t BMC nephrology \|d BioMed Central, 2000 \|g 25(2024), 1 vom: 19. Sept. \|w (DE-627)326643672 \|w (DE-600)2041348-8 \|x 1471-2369 \|7 nnns
773	1	8	\|g volume:25 \|g year:2024 \|g number:1 \|g day:19 \|g month:09
856	4	0	\|u https://dx.doi.org/10.1186/s12882-024-03751-3 \|m X:SPRINGER \|x Resolving-System \|z kostenfrei \|3 Volltext
912			\|a SYSFLAG_0
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
936	b	k	\|a 44.00 \|q VZ
951			\|a AR
952			\|d 25 \|j 2024 \|e 1 \|b 19 \|c 09

Indexfelder

author_variant	y n yn w w ww h z hz m l ml x z xz h n hn j l jl l x lx y l yl m y my
matchkey_str	article:14712369:2024----::fetfetadayifudeieyytmnakroifamt
hierarchy_sort_str	2024
bklnumber	44.00
publishDate	2024
allfields	10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09
spelling	10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09
allfields_unstemmed	10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09
allfieldsGer	10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09
allfieldsSound	10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09
language	English
source	Enthalten in BMC nephrology 25(2024), 1 vom: 19. Sept. volume:25 year:2024 number:1 day:19 month:09
sourceStr	Enthalten in BMC nephrology 25(2024), 1 vom: 19. Sept. volume:25 year:2024 number:1 day:19 month:09
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Maintenance hemodialysis Ultrapure dialysate Central Dialysate Delivery system CDDS Inflammation
dewey-raw	610
isfreeaccess_bool	true
container_title	BMC nephrology
authorswithroles_txt_mv	Ni, Yanhong @@aut@@ Wu, Wenhui @@aut@@ Zhou, Hua @@aut@@ Li, Min @@aut@@ Zhu, Xiying @@aut@@ Niu, Hongyan @@aut@@ Liu, Jinfeng @@aut@@ Xue, Lina @@aut@@ Liu, Yeqian @@aut@@ Yang, Min @@aut@@
publishDateDaySort_date	2024-09-19T00:00:00Z
hierarchy_top_id	326643672
dewey-sort	3610
id	SPR057390053
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR057390053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240920064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240920s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12882-024-03751-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR057390053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12882-024-03751-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ni, Yanhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maintenance hemodialysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultrapure dialysate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Dialysate Delivery system</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CDDS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Wenhui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Hua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Xiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niu, Hongyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Jinfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Lina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yeqian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC nephrology</subfield><subfield code="d">BioMed Central, 2000</subfield><subfield code="g">25(2024), 1 vom: 19. Sept.</subfield><subfield code="w">(DE-627)326643672</subfield><subfield code="w">(DE-600)2041348-8</subfield><subfield code="x">1471-2369</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:19</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12882-024-03751-3</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">19</subfield><subfield code="c">09</subfield></datafield></record></collection>
author	Ni, Yanhong
spellingShingle	Ni, Yanhong ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
authorStr	Ni, Yanhong
ppnlink_with_tag_str_mv	@@773@@(DE-627)326643672
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1471-2369
topic_title	610 VZ 44.00 bkl Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213
topic	ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation
topic_unstemmed	ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation
topic_browse	ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	BMC nephrology
hierarchy_parent_id	326643672
dewey-tens	610 - Medicine & health
hierarchy_top_title	BMC nephrology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)326643672 (DE-600)2041348-8
title	Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
ctrlnum	(DE-627)SPR057390053 (SPR)s12882-024-03751-3-e
title_full	Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
author_sort	Ni, Yanhong
journal	BMC nephrology
journalStr	BMC nephrology
lang_code	eng
isOA_bool	true
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
author_browse	Ni, Yanhong Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min
container_volume	25
class	610 VZ 44.00 bkl
format_se	Elektronische Aufsätze
author-letter	Ni, Yanhong
doi_str_mv	10.1186/s12882-024-03751-3
dewey-full	610
author2-role	verfasserin
title_sort	effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
title_auth	Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
abstract	Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024
abstractGer	Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024
abstract_unstemmed	Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024
collection_details	SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
url	https://dx.doi.org/10.1186/s12882-024-03751-3
remote_bool	true
author2	Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min
author2Str	Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min
ppnlink	326643672
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s12882-024-03751-3
up_date	2024-09-20T05:14:12.370Z
_version_	1810690738616270848
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR057390053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240920064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240920s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12882-024-03751-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR057390053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12882-024-03751-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ni, Yanhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant timegroup interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant timegroup interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maintenance hemodialysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultrapure dialysate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Dialysate Delivery system</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CDDS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Wenhui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Hua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Xiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niu, Hongyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Jinfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Lina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yeqian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC nephrology</subfield><subfield code="d">BioMed Central, 2000</subfield><subfield code="g">25(2024), 1 vom: 19. Sept.</subfield><subfield code="w">(DE-627)326643672</subfield><subfield code="w">(DE-600)2041348-8</subfield><subfield code="x">1471-2369</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:19</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12882-024-03751-3</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">19</subfield><subfield code="c">09</subfield></datafield></record></collection>
score	7.3986425

Nicht das Richtige dabei?

Schreiben Sie uns!

Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?